PrimeVigilance LTD   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Guildford United Kingdom (2008)

Organization Overview

First Clinical Trial
2018
NCT03195387
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

PrimeVigilance | PrimeVigilance LTD | PrimeVigilance Ltd., UK | PrimeVigilance Zagreb

Active Ingredients

Drugs in Phase 4 Trials (1)

padeliporfin (Tookad) (2 trials)

Drugs in Phase 2 Trials (1)

bisphosphocin nu-3 (1 trial)

Drugs in Phase 1 Trials (4)

artemether (1 trial)

lumefantrine (Coartem) (1 trial)

mmv390048 (1 trial)

p218 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 1)

Enuresis (Phase 4)

Erectile Dysfunction (Phase 4)

Infections (Phase 1)

Malaria (Phase 1)

Malaria, Falciparum (Phase 1)

Parasitemia (Phase 1)

Parasitic Diseases (Phase 1)

Prostatic Neoplasms (Phase 4)

Protozoan Infections (Phase 1)

Urinary Incontinence (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 6